BRCA1 and breast cancer: However, in women deemed to be at increased risk of developing breast cancer based on their family history or carrier status of a pathogenic genetic mutation (e.g. BRCA1/2), a survival benefit from CRRM has been shown, particularly in those with a pathogenic variant in BRCA1 and BRCA26–8 .